Drug Trial Radar · NCT07508787
A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jun 29, 2026
Primary completion
Mar 28, 2028
Study completion Mar 28, 2028
Sponsor
- Lead sponsor
- ITB-Med LLCIndustry
- Sponsor type
- Industry
- First posted
- Apr 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease. The main questions it aims to answer are: How many adverse events do participants receiving two different doses of siplizumab have compared to rabbit anti-thymocyte globulin (rATG)? How many participants successfully keep their kidney transplant after receiving siplizumab or rATG? This will be calculated as those participants that did not: die; have their kidney fail to work properly (graft loss); their body rejects their transplant (tissue sample (biopsy)-proven acute rejection: BPAR); or who were lost to follow-up. How does the body respond to siplizumab after dosing at each of the 2 dose levels? How does siplizumab work in the body compared to rATG? Selected participants will be divided into 3 groups. In 2 of the groups, participants will be given siplizumab at one of the two study medicine doses. Participants in the third group will be given rATG. All participants will take the usual anti-rejection medicines given before, during, and after a kidney transplant. All participants will also be given medicines before the study drug to lower the risk of reactions, and medicines used to prevent or treat infections after the transplant. Participants will be asked to provide their medical history at the first visit at the study site where you will have your kidney transplant. At the first visit and other visits participants will be asked to provide their medication history, have a physical exam, check vital signs, have blood drawn for tests, and have non-invasive tests that record the electrical activity of your heart (ECG) and blood draws. Participants will be monitored for 12 months after transplant surgery.
Conditions
- Renal Transplant Failure and Rejection
Interventions
SiplizumabDrug
A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class
Rabbit anti-thymocyte globulinDrug
An anti-human thymocyte immunoglobulin preparation made of purified polyclonal antibodies derived from rabbits
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of the safety of 2 dose levels of siplizumab versus rATG.Time frame: 12 months
Locations
27 sites in 3 countries. Site status is shown where the registry gives one.
Keck Hospital of the University of Southern California
Los Angeles, California · Recruiting
University of California - Los Angeles, Connie Frank Kidney Transplant Center
Los Angeles, California · Recruiting
UC Davis Medical Center
Sacramento, California · Recruiting
Tampa General Hospital
Tampa, Florida · Recruiting
Emory University Hospital
Atlanta, Georgia · Recruiting
University of Kansas Hospital
Kansas City, Kansas · Recruiting
University of Kentucky Healthcare
Lexington, Kentucky · Recruiting
Tulane Medical Center
Metairie, Louisiana · Recruiting
UMass Chan Medical Center
Worcester, Massachusetts · Recruiting
University of Michigan - Michigan Medicine
Ann Arbor, Michigan · Recruiting
Henry Ford Health
Detroit, Michigan · Recruiting
Cooperman Barnabus Medical Center
Livingston, New Jersey · Recruiting
New York Presbyterian - Columbia University Irving Medical School
New York, New York · Recruiting
New York Presbyterian - Weill Cornell Medical Center
New York, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas · Recruiting
Inova Fairfax Hospital
Falls Church, Virginia · Recruiting
Virginia Commonwealth University Health
Richmond, Virginia · Recruiting
University of Washington Medical Center
Seattle, Washington · Recruiting
Santa Casa Demisericordia de Belo Horizonte
Belo Horizonte, Minas Gerais, Brazil · Recruiting
Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vincente Scherer
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa
São José do Rio Preto, São Paulo, Brazil · Recruiting
Fundação Oswaldo Ramos - Hospital do Rim (HRIM)
São Paulo, São Paulo, Brazil · Recruiting
Hospital Universitari Vall D'Hebron
Barcelona, Spain · Recruiting
Hospital Universitario Reina Sofía
Córdoba, Spain · Recruiting
Hospital Universitario Regional de Malaga
Málaga, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.